This past decade has witnessed the remarkable advances in the understanding of the role of the erbB2 gene in cancers and the stunning progress in developing targeted therapies for erbB2-overexpressing cancers. Activation of the ErbB2 receptor signaling pathways can enhance various metastasis-associated properties that lead to an increase of cancer metastasis. Additionally, ErbB2 overexpression confers therapeutic resistance via receptor-mediated antiapoptotic signals. To limit these disastrous eects of the overexpressed ErbB2, various ErbB2-blocking strategies have been developed in the laboratories and several have been tested in clinical trials or approved as therapies for ErbB2 overexpressing cancers. In this article, we will discuss the detrimental eects of the erbB2 gene in cancers, with a focus on breast cancer. We will also outline ErbB2-targeting strategies as potential therapies for ErbB2-overexpressing cancers. Progress in understanding the molecular biology of ErbB2 and in molecular-based treatment of ErbB2-overexpressing tumors will bring great bene®ts to cancer patients. Oncogene (2000) 19, 6115 ± 6121.
Introduction
The erbB2 gene (also known as HER2, neu, and NGL) is one of the most studied molecules in the ®eld of cancer. The erbB2 gene encodes a 185-kDa transmembrane glycoprotein (p185 ErbB2 ), that belongs to the epidermal growth factor receptor (EGFR) family (Bargmann et al., 1986; Coussens et al., 1985; Yamamoto et al., 1986) . Similar to EGFR, the p185 erbB2 growth factor receptor has intrinsic tyrosine kinase activities Stern et al., 1986) . Although the ligand of the ErbB2 receptor has not been clearly de®ned, a neu-activating factor (NAF) that binds to neu receptor and an intramembrane modulator of the ErbB2 receptor (named ASGP2) that potentiates neuregulin-1 signaling have been reported (Carraway III et al., 1999; Samanta et al., 1994) . Notably, the ErbB2 receptor can mediate signal transductions of all ErbB receptor family members (EGFR, ErbB3, ErbB4) when they bind to their cognate ligands (Carraway et al., 1994; Graus-Porta et al., 1997; Plowman et al., 1993) . Thus, the ErbB2 receptor can mediate the lateral signal transduction of all ErbB receptors (Carraway et al., 1994; Graus-Porta et al., 1997; Plowman et al., 1993) . Furthermore, the ErbB2 receptor can be involved in the regulation of a variety of vital functions controlled by any of the ErbB-receptor family members, such as cell growth, dierentiation, and apoptosis.
The erbB2 gene plays an important role in human malignancies. It is ampli®ed and/or overexpressed in approximately 30% of human breast carcinomas (Slamon et al., 1987 (Slamon et al., , 1989 and in many other types of human malignancies . Studies of individuals with ErbB2-overexpressing tumors have shown that they have a signi®cantly poor clinical outcome compared to patients whose tumors did not overexpress ErbB2 (Berchuck et al., 1990; Slamon et al., 1987 Slamon et al., , 1989 . The molecular and cellular biological mechanisms underlying ErbB2 overexpression-mediated poor clinical outcome in cancer patients have emerged to involved at least two major mishaps. One is that overexpression of ErbB2 enhances metastasis-related properties (invasion, angiogenesis, increased survival) of cancer cells that will lead to increased cancer metastases (Figure 1 ). The other is that overexpression of ErbB2 confers cancer cells increased resistance to various cancer therapies (some chemotherapeutic agents, hormones, g-radiation, some cytokines) that will result in poor response to cancer treatment ( Figure 1 ).
ErbB2 overexpression and cancer metastasis
Both clinical and laboratory data indicated that overexpression of ErbB2 contributes to increased metastatic potential of cancer cells. Studies in nodepositive breast cancer patients revealed a correlation between the number of lymph node metastases and ErbB2 overexpression (Slamon et al., 1987 (Slamon et al., , 1989 . Experiments using transgenic mice showed that introduction of the erbB2 gene into mice can induce mammary tumors and metastases in mice (Guy et al., 1992; Suda et al., 1990) . Consistent with these observations, we found that expression of activated rat neu oncogene in 3T3 cells is sucient to induce experimental metastasis in nude mice (Yu and Hung, 1999) . Later, we demonstrated that overexpression of p185
ErbB2 could enhance the metastatic potential of human breast and lung cancer cells by experimental metastasis assays on a panel of breast cancer transfectants and lung cancer transfectants expressing dierent levels of p185
ErbB2 (Tan et al., 1997; Yu et al., 1994) . In addition, we and others have shown that: (1) ErbB2 overexpression can upregulate MMP-9 and MMP-2 protease activities and increase the invasiveness of breast cancer cells (Tan et al., 1997) ; (2) ErbB2 overexpression can increase VEGF expression in breast cancer cells, which, together with higher MMP-9
Oncogene (2000) 19, 6115 ± 6121 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: D Yu activity, may lead to stronger angiogenic response (Petit et al., 1997; and Yu et al., unpublished data) ; (3) ErbB2 overexpression can confer apoptosis resistance (survival advantage) in breast cancer cells (Yu et al., 1998a) . Together, upregulation of MMPs and angiogenesis as well as apoptosis resistance can contribute to increased metastatic potential.
Despite the progress in con®rming the role of ErbB2 overexpression in cancer metastasis, the molecular signaling mechanisms that are responsible for ErbB2-mediated cancer metastasis are largely unknown. In our initial eort along this line, we found that ErbB2-overexpression activates transcription and enhances secretion of MMP-9 proteases, that leads to increased membrane degradation and invasiveness of ErbB2-overexpressing breast cancer cells. Inhibition of p185
ErbB2 tyrosine kinase activities and/or downstream ERK activities using chemical inhibitors blocked ErbB2-mediated MMP-9 upregulation and invasion of breast cancer cells (Yu et al., unpublished observations) . Although our data is still preliminary, it provides some initial clues on the signaling of ErbB2 receptor leading to breast cancer metastasis. It is conceivable that multiple ErbB2 downstream signals (e.g., Shc/Grb-2-Ras, PI3K-Akt, MEK-ERK, JNK, p38MAPK, PKC, PLC etc.) are involved in inducing a variety of metastasis-related properties, that can contribute to higher metastatic potential of ErbB2-overexpressing cancer cells. Understanding and further manipulation of the signal transduction networks critical for ErbB2-mediated metastasis should facilitate the development of novel anti-metastasis therapies for ErbB2-overexpressing cancers.
ErbB2 and therapeutic resistance
Substantial evidences have been accumulated indicating that the erbB2 gene aects the sensitivity of cancer cells to various treatments, such as chemotherapy, hormone therapy, radiation therapy, and cytokine treatment.
Chemotherapy
Clinical investigations have shown that breast tumors overexpressing the erbB2 gene are less responsive than those expressing a normal amount of erbB2 to treatments including cyclophosphamide, methotrexate, and 5-¯uorouracil (CMF) or epirubicin (Gusterson et al., 1992; Jarvinen et al., 1998) . These suggested that the ErbB2 expression level could be used as a marker for response to chemotherapy for patients. Patients with node-positive early-stage breast tumors that overexpressed ErbB2 bene®ted from higher doses of chemotherapy, whereas patients with early-stage disease not exhibiting ErbB2 overexpression did not (Muss et al., 1994) . This suggested a relationship between chemosensitivity and p185
ErbB2 expression in breast cancers. Another study showed that the status of ErbB2 expression was useful for predicting survival time only in patients receiving adjuvant therapy, further suggesting that ErbB2 may be a marker of drug resistance (Tetu and Brisson, 1994) . In addition, elevated levels of circulating ErbB2 extra-cellular domain (ECD) in patients with metastatic breast cancers are associated with a lower rate of response to ®rst-line chemotherapy (Fehm et al., 1998) . The elevated serum levels of the ErbB2 ECD also correlate with reduced ecacy of breast cancers to adjuvant chemotherapies and a paclitaxel-doxorubicine chemotherapy combination (Colomer et al., 2000; Fehm et al., 1997; Mehta et al., 1998) .
Laboratory studies have more directly demonstrated that ErbB2 overexpression can render breast cancer cells resistant to certain chemotherapeutic agents. Using a panel of breast cancer cell lines established from dierent patients that express dierent levels of ErbB2 (Yu et al., 1998b) , we showed that higher levels of p185
ErbB2 expression in these cell lines correlated with increased resistance to taxol and docetaxel (Taxotere). Conversely, N29 monoclonal antibodies that can speci®cally downregulate p185
ErbB2 sensitized the p185-overexpressing breast cancer cells to taxol (Yu et al., 1998b) . Additionally, the above-described 435.eB transfectants that had increased expression of p185 ErbB2 also showed increased resistance to taxol and taxotere than their ErbB2 low-expressing parental MDA-MB-435 cells in vitro (P50.00012) and in vivo (unpublished observations). These lead to the conclusion that overexpression of p185
ErbB2 can confer intrinsic taxol resistance . These ®ndings are supported by another study in which Herceptin, the anti-ErbB2 antibody, enhanced the antitumor activity of taxol and doxorubicin against ErbB2-overexpressing human breast cancer xenografts . Furthermore, results of the Herceptin phase III trial demonstrated that the taxol response rate of patients with ErbB2-overexpressing breast cancers was signi®cantly higher among patients receiving taxol plus Herceptin than those receiving taxol alone .
It should be noted that there are controversies regarding ErbB2 and response to chemotherapy and hormonal therapy both in clinical investigations and laboratory studies (Nelson, 2000; Yu and Hung, 2000) . Many factors can contribute to the discordance in outcome of investigations regarding the role of erbB2 in modulating chemosensitivity . Nevertheless, sensitization to taxol by downregulation of ErbB2 with Herceptin strongly supported the role of ErbB2 in conferring taxol resistance. In further elucidating the molecular mechanisms underlying (1) promote various metastasis-related properties that lead to increased metastasis and (2) confer therapeutic resistance to a variety of cancer therapies that leads to poor response to cancer treatment. Thus, patients with ErbB2-overexpressing cancer have poor clinical outcome ErbB2-mediated taxol resistance, our data revealed that taxol can activate p34
Cdc2 kinase in MDA-MB-435 breast cancer cells, which is required for induction of apoptosis. On the other hand, overexpression of p185 ErbB2 in 435.eB transfectants inhibits the taxolmediated activation of p34
Cdc2 kinase and thus impedes taxol-induced apoptosis (Yu et al., 1998a) . It is plausible that ErbB2-mediated taxol resistance may involve multiple mechanisms that merit further indepth study.
Hormone therapy
The growth of certain types of human cancer cells (such as breast, ovarian, and prostate) are regulated by steroid hormones as well as peptide hormone receptors. Both clinical and laboratory data consistently demonstrated that the ErbB2 receptor may interplay with hormone receptors and may confer resistance to hormone therapy.
Clinical data have indicated that estrogen receptor positive (ER + ) breast cancer patients with increased serum ErbB2 levels are less responsive to hormone therapy than patients with non-detectable or low levels of ErbB2 (Leitzel et al., 1995) . Another study reported that pretreatment levels of serum ErbB2 predicted a low likelihood of bene®t from hormone therapy for patients with ER + and/or progesterone receptor (PgR)-positive or receptor-unknown metastatic breast cancers (Yamauchi et al., 1997) . In a laboratory study, MCF-7 breast cancer cells (ER + ) were transfected with full-length erbB2 cDNA resulting in a 2 ± 4-fold increase in resistance to cisplatin and resistant to the antiestrogen tamoxifen (TAM) (Benz et al., 1992) . In addition, the MCF/ErbB2 tumors in nude mice exhibited hormone-dependent, TAM-resistant growth. These data demonstrate a link between hormone receptors and growth factor receptors and suggest that overexpression of the ErbB2 receptor may contribute to resistance to hormone therapy in human breast cancers.
Overexpression of the erbB2 gene has been reported to be associated with an ER-negative phenotype and with low ER and PgR concentrations in the tumor cytosol (Pietras et al., 1995) . Introduction of an erbB2 cDNA to breast cancer cells resulted in estrogenindependent growth (insensitive to both estrogen and tamoxifen). Moreover, activation of the ErbB2 receptor by heregulin leads to direct and rapid phosphorylation of ER on tyrosine residues followed by ER interaction with the estrogen-response elements in the nucleus and expression of an estrogen-induced protein, PgR (Pietras et al., 1995) . In addition, overexpression of ErbB2 receptor in estrogen-dependent tumor cells promotes ligand-independent downregulation of ER. These data demonstrate a link between the two receptor pathways.
Not only can ErbB2 regulate ER but also ER can regulate ErbB2. We found that estrogen (E2) can negatively regulate the expression of p185 ErbB2 in two ER + but not an ER 7 breast cancer cell line(s) (Russell and Hung, 1992) . This regulation occurs at the transcriptional level and requires the presence of both ER and a 140-base pair estrogen-responsive region within the erbB2 promoter. This study provided evidence that the inverse clinical correlation between ErbB2 and ER expression may partially be due to transcriptional repression of erbB2 by E2/ER. In addition, the growth rate of ER + /ErbB2-overexpressing breast cancer cells was stimulated by E2 but the transformation phenotype was inhibited by E2, most likely due to downregulation of p185 ErbB2 (Russell et al., 1996) . ER + breast cancer patients are frequently treated with estrogen antagonists such as TAM. The rationale is that estrogen can stimulate growth of ER + tumor cells and TAM, by blocking interaction of estrogen with ER, should inhibit growth of ER + tumor cells. However, 50% of these patients do not respond to hormone treatment. Based on this clinical observation and our laboratory ®nding that estrogen has a dual eect on the ER + , ErbB-overexpressing breast cancer cells (i.e., stimulation of cell growth but suppression of transformation), we hypothesize that TAM may also have dual eects on the ER + /ErbB2-overexpressing cancer cells by blocking interaction of estrogen with ER . On one hand, TAM may inhibit the growth of ER + tumor cells; whereas on the other hand, TAM may enhance malignant transformation by increasing ErbB2 expression through counteracting ER suppression of erbB2 transcription. This hypothesis predicts that the subset of breast cancer patients who have ER + and ErbB2-overexpressing tumors may not respond to the TAM treatment. This hypothesis is supported by data from a nonrandomized study of 871 primary invasive breast tumors. The study showed that ErbB2 activation was signi®cantly correlated with poorer survival in the subgroup of patients with steroid receptor-positive tumors receiving adjuvant TAM therapy than in the untreated group (Borg et al., 1994) . The results suggest that steroid receptor-and ErbB2-positive breast tumors are resistant to TAM therapy. It has also been demonstrated that TAM administration can lead to ER-dependent upregulation of ErbB2 expression and growth stimulation (Borg et al., 1994) . Other experiments also indicate that antiestrogen can upregulate erbB2 expression by blocking ER (van Agthoven et al., 1994) , which accounts for resistance to hormone therapy of p185 ErbB2 -overexpressing breast cancer cells.
The link between hormone receptors and the ErbB2 receptor has recently been extended to the androgen receptor (AR). Androgen-independent prostate cancer sublines that expressed lower levels of AR were found to express higher levels of ErbB2 receptor compared with their androgen-dependent counterparts (Craft et al., 1999) . Forced overexpression of ErbB2 in androgen-dependent prostate cancer cells allowed ligandindependent growth by activation of the AR pathway in the absence of ligand and by synergizing with low levels of androgen to superactivate the pathway (Craft et al., 1999) . Thus, ErbB2 receptor can restore AR function to confer androgen-independence (hence resistance to endocrine therapy) in previously androgen-dependent prostate cancer cells.
Radiation therapy
Reports on the relationship between overexpression of ErbB2 and resistance to radiation therapy are limited. However, there are some evidences that ErbB2 may render cancer cells resistant to radiotherapy (Burke et al., 1998; Pirollo et al., 1997) . It has been suggested that ErbB2 may activate a signal transduction pathway, analogous to that for cell growth and dierentiation, that leads to the phenotype of cellular radioresistance (Pirollo et al., 1997) . Utilizing antisense oligonucleotides directed against the raf-1 signal transducer gene, radioresistance was reversed in human tumor cell lines having elevated ErbB2 expression. Antisense oligonucleotides directed against ras were also able to radiosensitize ErbB2 overexpressing cells. These data suggest that the ErbB2 receptor stimulate downstream signaling pathway(s) involving activation of ras and raf-1 leading to cellular radiation resistance.
In addition, we recently demonstrated that ErbB2 can activate NF-kB, which plays a critical role in the antiapoptotic pathways of radiation-induced apoptosis (Zhou et al., 2000) . We have also shown that girradiation eciently induced activation of NF-kB in the ErbB2-overexpressing SKOV3.ip1 ovarian cancer cells that are resistant to g-irradiation-mediated growth inhibition and apoptosis . However, SKOV3.ip1 cells transfected with E1A, that repressed ErbB2 expression and inhibited g-irradiation-induced activation of NF-kB, became sensitive to g-irradiationmediated growth inhibition and apoptosis .
Cytokine treatment
Overexpression of ErbB2 has been reported, more than 10 years ago, to confer resistance to tumor necrosis factor (TNF) and lymphokine-activated killer cells in mouse 3T3 cells and human cancer cells (Hudziak et al., 1988; Lichtenstein et al., 1990) . Our recent studies provided a molecular mechanism for ErbB2-mediated TNF resistance in cancer cells. ErbB2, without extracellular stimulation, can constitutively activate Akt and NF-kB anti-apoptotic pathways to confer resistance to TNF-induced apoptosis (Zhou et al., 2000) . Blocking of the Akt pathway by a dominantnegative Akt mutant sensitizes ErbB2-overexpressing cancer cells to TNF-induced apoptosis and inhibits NF-kB activation (Zhou et al., 2000) . In addition, inhibition of IkB kinases and hence NF-kB activation by E1A also sensitizes cancer cells to TNF-induced apoptosis (Shao et al., 1999) . These ®ndings indicate that ErbB2 constitutively activates the Akt/NF-kB anti-apoptotic signaling cascade that confers resistance of cancer cells to TNF and reduce host defenses against neoplasia. It is forseeable that future investigations will unravel whether ErbB2 confers resistance to other cytokines and undermines other host immune responses.
ErbB2-targeting strategies
Extensive studies demonstrated that overexpression of the ErbB2 receptor has detrimental roles in cancer that lead to poor clinical outcome of cancer patients ( Figure  1) . The ErbB2 receptor is thus an ideal target of novel cancer therapies. Several exciting strides have been made to develop erbB2-targeting strategies that block ErbB2 expression or function (Table 1) .
Anti-ErbB2 receptor antibodies
The concept of using anti-ErbB2 antibodies to block or down-regulate the receptor was developed 16 years ago (Drebin et al., 1985) . A series of elegant experiments demonstrated that anti-Neu p185 monoclonal antibodies (e.g., 7.16.4) can down-modulate Neu p185 expression in neu-transformed NIH3T3 cells and reverse their transformed phenotype and inhibit tumorigenicity in vivo (Drebin et al., 1985 (Drebin et al., , 1986 (Drebin et al., , 1998a . The anti-Neu p185 monoclonal antibodies (7.16.4) was also shown to inhibit metastasis of neutransformed 3T3 cells . In addition, a humanized antibody Herceptin (or Trastuzumab) was developed from anti-p185 ErbB2 murine monoclonal antibody (mMuAb 4D5) that also binds to the extracellular domain of ErbB2 and downregulate the expression of cell-surface ErbB2 proteins (Shepard et al., 1991) . Herceptin has demonstrated tumor inhibitory and chemosensitizing eects to taxol and several chemotherapeutic agents in preclinical studies and in phase II and phase III clinical trials (Baselga et al., 1996 Pegram et al., 1998; Pietras et al., 1998) . Currently, Herceptin the only U.S. FDA approved drug for treatment of cancers that overexpress ErbB2. One of the remaining questions, however, is this: how does Herceptin sensitize ErbB2-overexpressing breast cancer cells to taxol? Based on our understanding of the mechanisms of ErbB2-mediated taxol resistance, we hypothesize that Herceptin may sensitize cells to taxol-induced apoptosis by allowing ecient activation of p34 Cdc2 kinase and induction of apoptosis by taxol. We are currently testing this hypothesis. Binds to the extracellular domain of erbB2 receptor and reduces the cell surface erbB2 Ad5 E1A proteins Transcriptionally repress erbB2 gene expression ErbB2-directed suicide gene expression (e.g. erbB2-promoter driven cytosine deamiase gene) Utilizes transcriptional differences between normal and ErbB2-overexpressing cells to drive the selective expression of metabolic`suicide gene' that is able to convert a nontoxic prodrug into its toxic metabolite ErbB2-specific tyrosine kinase inhibitors (e.g. Emodin) Inhibits the tyrosine kinase activities of the erbB2 receptor tyrosine kinase Intracellular single-chain antibodies against ErbB2
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Transcriptional repression of erbB2 by adenovirus type 5 E1A
The E1A proteins of adenovirus type 5 were ®rst demonstrated by us to repress erbB2 gene expression at the transcriptional level (Yu et al., 1990) . E1A proteins inhibit ErbB2-overexpressing tumor growth and dissemination in animal models (Yu et al., , 1992 Zhang et al., 1997) . E1A can eectively inhibit metastases of ErbB2/neu overexpressing tumor cells (Yu et al., 1992 and sensitize these cells to chemotherapeutic agents (Ueno et al., 1997) , radiation therapy , and TNF induced-apoptosis (Shao et al,. 1999 ). Moreover, a phase I clinical trial has been performed using cationic liposome-mediated adenovirus type 5 E1A gene transfer to ErbB2-overexpressing human breast and ovarian cancer cells. This phase I trial has demonstrated biological eects, including downregulation of ErbB2 expression in tumors, expression of transduced E1A gene, reduced tumor cell clumps seen under microscope and increased apoptosis of tumor cells . Notably, E1A has been shown to have multiple tumor inhibitory mechanisms and also inhibits tumors that express normal levels of ErbB2 (Deng et al., 1998; Frisch, 1991; Frisch and Dolter, 1995; Mymryk, 1996; Shao et al., 1999) . This is supported by data from a recent multiple centers phase II clinical trial (sponsored by Target Genetics Inc.) for head and neck cancers that E1A produced promising therapeutic ecacy in cancers regardless of their ErbB2 status. It is our belief that E1A promises to bring new therapeutic bene®t to cancer. Similarly, the Ets protein, PEA3, also suppresses ErbB2/neu overexpression at transcription level and inhibits tumorigenesis of ErbB2/neu overexpressing cancer cells (Xing et al., 2000) . Thus, it may provide an alternative approach to target ErbB2.
ErbB2-directed suicide gene expression
ErbB2-overexpressing cancer cells are believed to contain transcription factors (e.g., AP-2) that strongly activate the erbB2 promoter and genetic prodrug activation therapies have been developed that exploit this transcriptional pro®le of ErbB2-overexpressing cancer cells (Harris et al., 1994) . A therapeutic cassette containing the E. coli cytosine deaminase`suicide gene' driven by the erbB2 promoter has been used to activate the prodrug¯uorocytosine to the active cytotoxic uorouracil only in the ErbB2-overexpressing tumor cells. This transcriptionally targeted prodrug activation therapy has been tested in a phase I clinical trial using direct intratumor injection of the therapeutic cassette combined with systemic administration of prodruḡ uorocytosine in patients with ErbB2-overexpressing breast cancers (Pandha et al., 1999) . The approach was determined to be safe and signi®cant levels of expression of the suicide gene were speci®cally restricted to ErbB2 positive tumor cells (Pandha et al., 1999) .
ErbB2-specific tyrosine kinase inhibitors
Overexpression of the ErbB2 receptor can lead to increased tyrosine kinase activities triggering downstream signaling pathways and subsequent biological functions. Therefore, there have been intensive investigations on inhibitors of the ErbB2 tyrosine kinase activities (Fry et al., 1998; Noonberg and Benz, 2000) . Among the many inhibitors identi®ed, we have found that emodin (3-methyl-1,6,8-trihydroxyanthraquinone) suppresses the autophosphorylation and transphosphorylation activities of ErbB2 tyrosine kinase in ErbB2-overexpressing breast cancer cells and results in suppression of tumor growth (Zhang et al., 1995) . Similarly, curcumin, a natural compound present in turmeric, was shown to inhibit the tyrosine kinase activity of p185 ErbB2 by depleting p185 ErbB2 and it inhibited growth of p185
ErbB2
-overexpressing breast cancer cell lines (Hong et al., 1999) . Several clinical trials are ongoing to validate the ecacy of tyrosine kinase inhibitors in the treatment of ErbB2-overexpressing breast cancers (Noonberg and Benz, 2000) .
Anti-ErbB2 intracellular single-chain antibodies
Successful eorts have been made to downregulate the expression of the ErbB2 receptor or eradicate it from the cell surface membrane using gene constructs encoding anti-ErbB2 intracellular single-chain antibodies (Barnes et al., 1996; Haynes et al., 1999; Huston et al., 1993) . Recombinant adenoviruses encoding the endoplasmic reticulum-directed anti-ErbB2 intracellular single-chain antibodies (sFv) were markedly cytotoxic (60 to 95% of cells) in ErbB2-overexpressing human breast cancer cells (Wright et al., 1997) . The single-chain antibodies also induced apoptosis in ErbB2-overexpressing cells, that was secondary to the intracellular antibody-mediated ectopic localization of the ErbB2 protein .
Anti-HER2/ErbB2/Neu peptide mimetics
Remarkable eorts have been made to design peptide mimetics using the heavy chain CDR3 of human antiErbB2/HER2 antibody as template from the crystal structure of Herceptin. The anti-ErbB2/HER2/Neu peptide mimetics (AHNP) have similar folding as that of the parent antibody and were shown to downmodulate cell surface ErbB2 receptor and inhibit cell proliferation and transformation (Park et al., 2000) . It is conceivable that the AHNP may not only be developed into anti-ErbB2/HER2 therapeutics but may also be used as ErbB2-targeting peptides when conjugated to other types of therapeutics.
Downregulation of ErbB2 by retinoic acid
Retinoic acid has shown preventive and even therapeutic eects in several laboratory and clinical studies. It also induces apoptosis in various cancer types. Interestingly, all-trans retinoic acid (ATRA) and fenretinide (4-HPR) have been shown to downregulate ErbB2 protein and mRNA in ErbB2-overexpressing SKBR3 and BT474 breast cancer cells as well as in MCF-7 cells that express lower levels of ErbB2. Moreover, 4-HPR plus cisplatin has been shown to be more eective in inhibiting the growth of ErbB2-overexpressing cells than either agent alone (Grunt et al., 1998) . Recently, retinoic analogues were also shown to delay mammary tumor development in cneu transgenic mice (Rao et al., 1999) .
DNA vaccines against ErbB2/HER2/neu
ErbB2/HER2/neu DNA vaccines that induce immune response against ErbB2-overexpressing breast cancers have also shown some promises. It has recently been reported that DNA vaccination with full length or truncated neu gene eectively induced protective immunity against the development of spontaneous mammary tumors in ErbB2/HER2/neu transgenic mice (Amici et al., 2000) .
Antisense oligonucleotides and antisense RNAs of ErbB2
Antisense oligonucleotides and antisense RNAs block erbB2 gene transcription. These have been shown to induce apoptosis after DNA damage and to lower ErbB2 expression in ErbB2-overexpressing cancer cells (Giannois and Ioannidou-Mouzaka, 1997) .
In addition, immunotoxins and ligand-binding cytotoxic agents using the extracellular domain of ErbB2 have been developed for targeted cancer therapies (Noonberg and Benz, 2000) . Taken together, these combined eorts in developing ErbB2-targeting strategies for cancer therapies will bring revolution in therapies for patients with ErbB2-overexpressing breast tumors.
In summary, recognizing that (a) overexpression of the ErbB2 receptor has detrimental roles leading to increased cancer metastasis and patients' poor response to anticancer therapies (Figure 1) , and (b) life expectancy for cancer patients with ErbB2 overexpressing tumors is limited, development of novel ErbB2-targeting therapies may provide remedies for cancer patients with ErbB2 overexpressing tumors (Table 1) . We are witnessing early victories in the war against ErbB2-overexpressing cancers, yet it is just`the end of the beginning' (King, 1998) .
